With Or Without Generic Competition, Allergan’s CEO Sees Growth Ahead
This article was originally published in The Pink Sheet Daily
Executive Summary
Prospects for its key ophthalmic drug Restasis are still up in the air, despite recent positive news, but Allergan CEO expects double-digit sales and earnings growth for the next five years, driven by operating efficiencies and creation of new markets.